Michael Allgauer
Overview
Explore the profile of Michael Allgauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
2212
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Niedermaier B, Allgauer M, Muley T, Schneider M, Eichhorn M, Winter H, et al.
Thorac Cancer
. 2025 Jan;
16(1):e15536.
PMID: 39807578
Objective: Among the different subtypes of invasive lung adenocarcinoma, lepidic predominant adenocarcinoma (LPA) has been recognized as the lowest-risk subtype with good prognosis. The aim of this study is to...
2.
Ball M, Romanovsky E, Schnecko F, Kirchner M, Neumann O, Brandt R, et al.
J Mol Diagn
. 2024 Dec;
27(2):154-162.
PMID: 39674366
The adoption of comprehensive genomic profiling in oncology has rapidly increased the demand for standardized tumor sample processing in diagnostic laboratories. Automation of DNA and RNA library preparation workflows offers...
3.
Milenkovic I, Cruciani S, Llovera L, Lucas M, Medina R, Pauli C, et al.
Mol Cell
. 2024 Dec;
85(1):177-190.e7.
PMID: 39662470
Mammalian ribosomal RNA (rRNA) molecules are highly abundant RNAs, decorated with over 220 rRNA modifications. Previous works have shown that some rRNA modification types can be dynamically regulated; however, how...
4.
Saalfeld F, Moller J, Christopoulos P, Wenzel C, Rasokat A, Wang X, et al.
Eur J Cancer
. 2024 Oct;
213:115065.
PMID: 39423775
Introduction: Small cell transformation (SCT) is a typical mechanism of adaptive resistance to third generation epidermal growth factor receptor inhibitors (EGFRi) which have become the standard of care for EGFR-driven...
5.
Klotz L, Weigert A, Eichhorn F, Allgauer M, Muley T, Shah R, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39410037
Immunotherapy has significantly improved overall survival in patients with pleural mesothelioma, yet this benefit does not extend to those with the epithelioid subtype. Tumor growth is believed to be influenced...
6.
Budczies J, Kazdal D, Menzel M, Beck S, Kluck K, Altburger C, et al.
Nat Rev Clin Oncol
. 2024 Aug;
21(10):725-742.
PMID: 39192001
Tumour mutational burden (TMB), defined as the total number of somatic non-synonymous mutations present within the cancer genome, varies across and within cancer types. A first wave of retrospective and...
7.
Safi S, Gysan M, Weber D, Behnisch R, Muley T, Allgauer M, et al.
World J Surg Oncol
. 2024 Aug;
22(1):213.
PMID: 39118130
Background: Reports from case series suggest that operative outcomes are comparable amongst different age groups following surgery with curative intent for non-small cell lung cancer (NSCLC). The purpose of this...
8.
Abers M, Vo P, Allgauer M, Manion M, Butman J, Bishop R, et al.
J Infect
. 2024 Jul;
89(2):106214.
PMID: 38955247
No abstract available.
9.
Blasi M, Kuon J, Luders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, et al.
Eur J Cancer
. 2024 May;
205:114130.
PMID: 38789333
No abstract available.
10.
Ball M, Ourailidis I, Kluck K, Menzel M, Kirchner M, Allgauer M, et al.
J Mol Diagn
. 2024 Mar;
26(6):479-486.
PMID: 38522840
Targeted tumor only sequencing has become a standard practice in cancer diagnostics. This study aims to develop an approach for robust copy number variant calling in tumor samples using only...